John Taylor, III, MD, on novel options in NMIBC

In a recent interview with Urology Times®, John A. Taylor, III, MD, MS, discussed the new wealth of options in non–muscle invasive bladder cancer (NMIBC). The current landscape, he notes, is a stark contrast to 15 years ago, when options for these patients were limited.

With these new treatment modalities comes the need to understand how and when to use each agent. Efficacy data appear to be similar, so there are other considerations that need to factor into choosing the best option for each patient, he explained.

Taylor is a professor of urologic surgery at the University of Kansas Medical Center in Kansas City.

Now Viewing

EP: 1.John Taylor, III, MD, on novel options in NMIBC

EP: 2.Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer

One of the emerging options in this space is detalimogene voraplasmid (EG-70), which is currently in phase 1/2 development for the treatment of patients with BCG-unresponsive NMIBC. EG-70 is a non-viral gene therapy that is designed to stimulate both the innate and adaptive immune response.

The therapy is currently being assessed in the LEGEND trial (NCT04752722), which recently reported initial safety and efficacy in the BCG-unresponsive NMIBC population.¹ Overall, EG-70 boasted a complete response rate at any time point of 71%. At 3 and 6 months, these rates were 67% and 47%, respectively. Treatment was also well-tolerated, with all treatment-related adverse events being grade 1-2.

REFERENCE

1. Taylor JA, Joshi S, Satkunasivam R, et al. Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Presented at: 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. San Francisco, California. February 14-16, 2025. Abstract 802